Candel Therapeutics (CADL) Other Non-Current Assets (2020 - 2025)

Candel Therapeutics has disclosed Other Non-Current Assets across 6 years of filings, most recently posting $416000.0 for Q4 2025.

• Other Non-Current Assets for Q4 2025 came in at $416000.0, up 560.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $416000.0 (up 560.32% YoY), and the FY2025 annual result was $416000.0, up 560.32% from the prior year.
• Other Non-Current Assets came in at $416000.0 for Q4 2025 at Candel Therapeutics, up from $300000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $1.7 million in Q2 2021 to a low of $45000.0 in Q2 2025.
• The 5-year median for Other Non-Current Assets is $266000.0 (2022), against an average of $331473.7.
• Peak annual rise in Other Non-Current Assets reached 560.32% in 2025, while the deepest fall reached 85.0% in 2025.
• Candel Therapeutics' Other Non-Current Assets stood at $400000.0 in 2021, then sank by 33.5% to $266000.0 in 2022, then grew by 12.78% to $300000.0 in 2023, then tumbled by 79.0% to $63000.0 in 2024, then surged by 560.32% to $416000.0 in 2025.
• The last three Other Non-Current Assets figures came in at $416000.0 (Q4 2025), $300000.0 (Q3 2025), and $45000.0 (Q2 2025), per Business Quant data.